[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MXPA04000407A - Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales. - Google Patents

Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales.

Info

Publication number
MXPA04000407A
MXPA04000407A MXPA04000407A MXPA04000407A MXPA04000407A MX PA04000407 A MXPA04000407 A MX PA04000407A MX PA04000407 A MXPA04000407 A MX PA04000407A MX PA04000407 A MXPA04000407 A MX PA04000407A MX PA04000407 A MXPA04000407 A MX PA04000407A
Authority
MX
Mexico
Prior art keywords
phenylacetamido
preparation
antitumor agents
thiazole derivatives
compounds
Prior art date
Application number
MXPA04000407A
Other languages
English (en)
Inventor
Nesi Marcella
Original Assignee
Pharmacia & Italia S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Italia S P A filed Critical Pharmacia & Italia S P A
Publication of MXPA04000407A publication Critical patent/MXPA04000407A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Compuestos representados por la formula (I), de acuerdo con lo definido en la descripcion, donde R es un atomo de hidrogeno o un grupo metilo y R1 es un grupo de acuerdo con lo definido en la especificacion, o una sal farmaceuticamente aceptable del mismo; dichos compuestos son utiles para el tratamiento de trastorno proliferativo celular, por ejemplo, cancer, asociado con una actividad de quinasa dependiente de ciclo celular alterado.
MXPA04000407A 2001-07-19 2002-07-02 Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales. MXPA04000407A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90794701A 2001-07-19 2001-07-19
US35764202P 2002-02-20 2002-02-20
PCT/EP2002/007289 WO2003008365A2 (en) 2001-07-19 2002-07-02 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents

Publications (1)

Publication Number Publication Date
MXPA04000407A true MXPA04000407A (es) 2004-03-18

Family

ID=26999733

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000407A MXPA04000407A (es) 2001-07-19 2002-07-02 Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales.

Country Status (25)

Country Link
US (1) US20040235919A1 (es)
EP (1) EP1406899B1 (es)
JP (1) JP2004534857A (es)
KR (1) KR100908794B1 (es)
CN (1) CN1286835C (es)
AR (1) AR036176A1 (es)
AT (1) ATE345341T1 (es)
AU (1) AU2002325860B2 (es)
BR (1) BR0211265A (es)
CA (1) CA2453294A1 (es)
CY (1) CY1105948T1 (es)
CZ (1) CZ2004107A3 (es)
DE (1) DE60216097T2 (es)
DK (1) DK1406899T3 (es)
EA (1) EA007392B1 (es)
ES (1) ES2274076T3 (es)
GE (1) GEP20105095B (es)
HK (1) HK1068336A1 (es)
IL (2) IL159570A0 (es)
MX (1) MXPA04000407A (es)
NO (1) NO20040210L (es)
NZ (1) NZ530524A (es)
PL (1) PL367938A1 (es)
PT (1) PT1406899E (es)
WO (1) WO2003008365A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2576599A1 (en) * 2004-08-17 2006-02-23 F. Hoffmann-La Roche Ag Substituted hydantoins
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
TW201408641A (zh) 2012-05-21 2014-03-01 Novartis Ag 可作爲激酶抑制劑之新穎環取代ｎ－吡啶基醯胺
WO2014085607A1 (en) 2012-11-29 2014-06-05 Karyopharm Therapeutics Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
WO2015003166A1 (en) 2013-07-03 2015-01-08 Karyopharm Therapeutics Inc. Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
WO2015042414A1 (en) * 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
AU2016308829A1 (en) 2015-08-18 2018-03-08 Karyopharm Therapeutics Inc. (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
US10858347B2 (en) 2015-12-31 2020-12-08 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
BR112021004999A2 (pt) * 2018-09-17 2021-06-08 Yungjin Pharm. Co., Ltd. composto e método de inibição de cdk7 em um sujeito
KR102335637B1 (ko) * 2020-03-13 2021-12-06 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염
CN112979636A (zh) * 2021-02-06 2021-06-18 绍兴文理学院 一种含苯硫醚结构的噻唑类化合物及其制备方法和应用
CN112979634A (zh) * 2021-02-06 2021-06-18 绍兴文理学院 一种含酰胺结构的噻唑类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) * 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents

Also Published As

Publication number Publication date
ATE345341T1 (de) 2006-12-15
AR036176A1 (es) 2004-08-18
ES2274076T3 (es) 2007-05-16
CN1286835C (zh) 2006-11-29
DE60216097D1 (de) 2006-12-28
NO20040210L (no) 2004-03-03
EA200400208A1 (ru) 2004-06-24
DK1406899T3 (da) 2007-04-02
WO2003008365A2 (en) 2003-01-30
HK1068336A1 (en) 2005-04-29
GEP20105095B (en) 2010-10-25
CN1531535A (zh) 2004-09-22
CY1105948T1 (el) 2011-04-06
BR0211265A (pt) 2004-07-20
KR20040030821A (ko) 2004-04-09
IL204947A0 (en) 2010-11-30
US20040235919A1 (en) 2004-11-25
EP1406899A2 (en) 2004-04-14
DE60216097T2 (de) 2007-06-28
WO2003008365A3 (en) 2004-02-12
EA007392B1 (ru) 2006-10-27
CA2453294A1 (en) 2003-01-30
PT1406899E (pt) 2007-01-31
KR100908794B1 (ko) 2009-07-22
NZ530524A (en) 2006-12-22
EP1406899B1 (en) 2006-11-15
CZ2004107A3 (cs) 2004-04-14
IL159570A0 (en) 2004-06-01
JP2004534857A (ja) 2004-11-18
PL367938A1 (en) 2005-03-07
AU2002325860B2 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
GEP20053476B (en) 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
RS20050462A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
MXPA02012166A (es) Derivados de azaindol, proceso para su preparacion y su uso como agentes antitumor.
MXPA04000407A (es) Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales.
AP1853A (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents.
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
TW200517109A (en) Substituted pyridinones
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
NZ527123A (en) Oxazolyl-pyrazole derivatives as kinase inhibitors
GB0119249D0 (en) Organic compounds
TW200502230A (en) Dual nk1/nk3 derivatives
PT1159279E (pt) 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais
NZ544514A (en) Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors
TW200503712A (en) (2-carboxamido)(3-amino)thiophene compounds
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
WO2002070515A3 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
ZA200900165B (en) 4-amino-3-arylamino-6-arylpyrazolo[3,4-D]pyrimidine derivatives, methods for their preparation and their use as antiviral agents
EP1724270A3 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
RS47004A (en) Hexacyclic compounds
NO20063353L (no) 1,2,3,4-tetrahydroisokinolinderivater, fremgangsmate for fremstilling derav og anvendelser derav
MX2007007485A (es) Derivados de cromano y usos de los mismos en el tratamiento de trastornos del sistema nervioso central.
UA81405C2 (en) Substituted pyridinones as modulators of p38 map kinase
AU2002359762A1 (en) Luminacin analogs and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration